Exact Sciences (EXCS) Q4 Net Loss Shrinks Amid Revenue Increase

Exact Sciences (EXCS) reported a narrower net loss of $19.2 million in Q4 2025, versus a $22.8 million loss in the same period of 2024, as revenue rose to $223.4 million, up from $208.1 million in Q4 2024. The improvement followed continued growth in its genomic testing and data analytics services, with revenue growth accelerating in the fourth quarter. Management attributed the better results to higher pricing and broader adoption of its cloud-based data solutions.